This Article Full Text Full Text (PDF) All Versions of this Article: 115/12/1528    most recent CIRCULATIONAHA.106.649939v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Search for Related Content PubMed PubMed Citation Articles by Sabatine, M. S. Related Collections Chronic ischemic heart disease

(Circulation. 2007;115:1528-1536.)
© 2007 American Heart Association, Inc.

Coronary Heart Disease

Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease

Marc S. Sabatine, MD, MPH; David A. Morrow, MD, MPH; Kathleen A. Jablonski, PhD; Madeline Murguia Rice, PhD; J. Wayne Warnica, MD; Michael J. Domanski, MD; Judith Hsia, MD; Bernard J. Gersh, MD; Nader Rifai, PhD; Paul M Ridker, MD; Marc A. Pfeffer, MD, PhD; Eugene Braunwald, MD, for the PEACE Investigators

From the Cardiovascular Division, Brigham and Women’s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass (M.S.S., D.A.M., P.M.R., M.A.P., E.B.); George Washington University, Rockville, Md, and Washington, DC (K.A.J., M.M.R., J.H.); Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada (J.W.W.); National Heart, Lung, and Blood Institute, Bethesda, Md (M.J.D.); Mayo Clinic Foundation, Rochester, Minn (B.J.G.); and Department of Laboratory Medicine and Pathology, Children’s Hospital, Boston, Mass (N.R.).

Correspondence to Marc S. Sabatine, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine{at}partners.org

Received July 6, 2006; accepted January 5, 2007.

Background— Data supporting the prognostic significance of high-sensitivity C-reactive protein (hs-CRP) are derived largely from individuals with no overt coronary artery disease or from patients with acute coronary syndromes. In contrast, the ability of hs-CRP to predict outcomes in patients with stable coronary artery disease and the prognostic significance of the Centers for Disease Control/American Heart Association hs-CRP cut points in such a population remain relatively unexplored.

Methods and Results— We measured hs-CRP in 3771 patients with stable coronary artery disease from the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) trial, a randomized placebo-controlled trial of the angiotensin-converting enzyme inhibitor trandolapril. Patients were followed up for a median of 4.8 years for cardiovascular death, myocardial infarction, or stroke, as well as new heart failure and diabetes. After adjustment for baseline characteristics and treatments, higher hs-CRP levels, even >1 mg/L, were associated with a significantly greater risk of cardiovascular death, myocardial infarction, or stroke (hs-CRP 1 to 3 mg/L: adjusted hazard ratio, 1.39; 95% CI, 1.06 to 1.81; P=0.016; hs-CRP >3 mg/L: adjusted hazard ratio, 1.52; 95% CI, 1.15 to 2.02; P=0.003). Similarly, elevated hs-CRP levels were an independent predictor of new heart failure (adjusted P<0.001 for trend) and new diabetes (adjusted P<0.001 for trend). There were no significant interactions between hs-CRP levels and the effects of trandolapril on any of the above outcomes.

Conclusions— In stable coronary artery disease, an elevated hs-CRP level, even >1 mg/L, is a significant predictor of adverse cardiovascular events independently of baseline characteristics and treatments. An elevated hs-CRP does not appear to identify patients with stable coronary artery disease and preserved ejection fraction who derive particular benefit from angiotensin-converting enzyme inhibition.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				E. A. Van Vre, H. Bult, V. Y. Hoymans, V. F.I. Van Tendeloo, C. J. Vrints, and J. M. Bosmans Human C-Reactive Protein Activates Monocyte-Derived Dendritic Cells and Induces Dendritic Cell-Mediated T-Cell Activation Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 511 - 518. [Abstract] [Full Text] [PDF]

				P. A. Kavsak, D. T. Ko, A. M. Newman, G. E. Palomaki, V. Lustig, A. R. MacRae, and A. S. Jaffe Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide Clin. Chem., December 1, 2007; 53(12): 2112 - 2118. [Abstract] [Full Text] [PDF]

				M. Kivimaki, D. A. Lawlor, G. D. Smith, C. Eklund, M. Hurme, T. Lehtimaki, J. S. A. Viikari, and O. T. Raitakari Variants in the CRP Gene as a Measure of Lifelong Differences in Average C-Reactive Protein Levels: The Cardiovascular Risk in Young Finns Study, 1980 2001 Am. J. Epidemiol., October 1, 2007; 166(7): 760 - 764. [Abstract] [Full Text] [PDF]